Bhattacharya R., Rao S., and Kowdley K.V. Liver involvement in patients with solid tumors of nonhepatic origin. Clin Liver Dis 6 4 (2002) 1033-1043 x
Pawlik T.M., Schulick R.D., and Choti M.A. Expanding criteria for resectability of colorectal liver metastases. Oncologist 13 1 (2008) 51-64
Lim L., Gibbs P., Yip D., et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer 5 (2005) 132
Lewandowski R.J., Thurston K.G., Goin J.E., et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol 16 12 (2005) 1641-1651
Kuvshinoff B., and Fong Y. Surgical therapy of liver metastases. Semin Oncol 34 3 (2007) 177-185
Choi J. Imaging of hepatic metastases. Cancer Control 13 1 (2006) 6-12
Dietrich C.F., Kratzer W., Strobe D., et al. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 12 11 (2006) 1699-1705
Albrecht T., Blomley M.J., Burns P.N., et al. Improved detection of hepatic metastases with pulse-inversion US during the liver-specific phase of SHU 508A: multicenter study. Radiology 227 2 (2003) 361-370
Albrecht T., Hoffmann C.W., Schmitz S.A., et al. Phase-inversion sonography during the liver-specific late phase of contrast enhancement: improved detection of liver metastases. AJR Am J Roentgenol 176 5 (2001) 1191-1198
Soyer P., Poccard M., Boudiaf M., et al. Detection of hypovascular hepatic metastases at triple-phase helical CT: sensitivity of phases and comparison with surgical and histopathologic findings. Radiology 231 2 (2004) 413-420
Sheafor D.H., Frederick M.G., Paulson E.K., et al. Comparison of unenhanced, hepatic arterial-dominant, and portal venous-dominant phase helical CT for the detection of liver metastases in women with breast carcinoma. AJR Am J Roentgenol 172 4 (1999) 961-968
van Erkel A.R., Pijl M.E., van den Berg-Huysmans A.A., et al. Hepatic metastases in patients with colorectal cancer: relationship between size of metastases, standard of reference, and detection rates. Radiology 224 2 (2002) 404-409
Kamel I.R., Georgiades C., and Fishman E.K. Incremental value of advanced image processing of multislice computed tomography data in the evaluation of hypervascular liver lesions. J Comput Assist Tomogr 27 4 (2003) 652-656
Rappeport E.D., Loft A., Berthelsen A.K., et al. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 48 4 (2007) 369-378
Namasivayam S., Martin D.R., and Saini S. Imaging of liver metastases: MRI. Cancer Imaging 7 (2007) 2-9
Kim H.J., Kim K.W., Byun J.H., et al. Comparison of mangafodipir trisodium- and ferucarbotran-enhanced MRI for detection and characterization of hepatic metastases in colorectal cancer patients. AJR Am J Roentgenol 186 4 (2006) 1059-1066
Choi J.Y., Kim M.J., Kim J.H., et al. Detection of hepatic metastasis: manganese- and ferucarbotran-enhanced MR imaging. Eur J Radiol 60 1 (2006) 84-90
Bartolozzi C., Donati F., Cioni D., et al. Detection of colorectal liver metastases: a prospective multicenter trial comparing unenhanced MRI, MnDPDP-enhanced MRI, and spiral CT. Eur Radiol 14 1 (2004) 14-20
Ward J., Robinson P.J., Guthrie J.A., et al. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology 237 1 (2005) 170-180
Schima W., Kulinna C., Langenberger H., et al. Liver metastases of colorectal cancer: US, CT or MR?. Cancer Imaging 5 Spec No A (2005) S149-S156
Yonekura Y., Benua R.S., Brill A.B., et al. Increased accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in liver metastases from colon carcinoma. J Nucl Med 23 12 (1982) 1133-1137
Delbeke D., Martin W.H., Sandler M.P., et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 133 5 (1998) 510-515 [discussion: 5-6]
Hustinx R., Paulus P., Jacquet N., et al. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol 9 4 (1998) 397-401
Lai D.T., Fulham M., Stephen M.S., et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 131 7 (1996) 703-707
Vitola J.V., Delbeke D., Sandler M.P., et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 171 1 (1996) 21-26
Kinkel K., Lu Y., Both M., et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 224 3 (2002) 748-756
Bipat S., van Leeuwen M.S., Comans E.F., et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 237 1 (2005) 123-131
Wiering B., Krabbe P.F., Jager G.J., et al. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 104 12 (2005) 2658-2670
Wiering B., Ruers T.J., Krabbe P.F., et al. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol 14 2 (2007) 818-826
Fernandez F.G., Drebin J.A., Linehan D.C., et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240 3 (2004) 438-447 [discussion: 47-50]
Riedl C.C., Akhurst T., Larson S., et al. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 48 5 (2007) 771-775
Cohade C., Osman M., Leal J., et al. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 44 11 (2003) 1797-1803
Selzner M., Hany T.F., Wildbrett P., et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann Surg 240 6 (2004) 1027-1034 [discussion: 35-6]
Lubezky N., Metser U., Geva R., et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 11 4 (2007) 472-478
Kong G., Jackson C., Koh D.M., et al. The use of (18) F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 35 7 (2008) 1323-1329
Chua S.C., Groves A.M., Kayani I., et al. The impact of 18F-FDG PET/CT in patients with liver metastases. Eur J Nucl Med Mol Imaging 34 12 (2007) 1906-1914
Soyka J.D., Veit-Haibach P., Strobel K., et al. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?. J Nucl Med 49 3 (2008) 354-361
Kuehl H., Rosenbaum-Krumme S., Veit-Haibach P., et al. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography. Nucl Med Commun 29 7 (2008) 599-606
Veit P., Antoch G., Stergar H., et al. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol 16 1 (2006) 80-87
Anderson G.S., Brinkmann F., Soulen M.C., et al. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 28 3 (2003) 192-197
Travaini L.L., Trifiro G., Ravasi L., et al. Role of [(18)F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging 35 7 (2008) 1316-1322
Kuehl H., Antoch G., Stergar H., et al. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol 67 2 (2008) 362-371
Wong C.Y., Salem R., Qing F., et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 45 11 (2004) 1892-1897